GH Research (NASDAQ:GHRS) Posts Quarterly Earnings Results

GH Research (NASDAQ:GHRS) posted its earnings results on Friday. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.13, FiscalAI reports.

GH Research Price Performance

Shares of GHRS stock traded up $0.93 during midday trading on Friday, reaching $19.42. 390,056 shares of the company traded hands, compared to its average volume of 303,355. The firm’s 50 day simple moving average is $22.48 and its two-hundred day simple moving average is $21.63. The firm has a market cap of $1.33 billion, a PE ratio of -19.41 and a beta of 1.31. GH Research has a 1-year low of $12.04 and a 1-year high of $31.44.

Wall Street Analyst Weigh In

GHRS has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating on shares of GH Research in a research report on Monday, August 10th. Zacks Research upgraded GH Research from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Wells Fargo & Company began coverage on GH Research in a report on Monday, July 27th. They issued an “overweight” rating and a $44.00 price objective for the company. Guggenheim raised their target price on shares of GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $44.36.

About GH Research

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.